Female nonsmokers exposed to passive smoking >30 years have increased risk of lung cancer
the ONA take:
According to a new study published in the journal Annals of Oncology, researchers from Stanford University School of Medicine in Stanford, California, have found that women who are exposed to smoking in the home for greater than 30 years have an increased risk for developing lung cancer despite having never smoked compared with women who were not exposed to passive smoking.
For the study, researchers identified 76,304 women between the ages 50 and 79 years. Of those, 6.2% were current smokers, 41.68% were former smokers, 47.36% were nonsmokers but exposed to passive smoking, and 4.77% were never smokers and had no exposure to passive smoking. The women were followed for an average of 10.5 years.
During that time, 901 women developed lung cancer. Results showed that current smokers were 13.44 times more likely to develop lung cancer compared with never-smokers, and former smokers were 4.2 times more likely than never-smokers.
There was no statistically significant difference of risk between non-smokers with passive smoking exposure and those without passive smoking exposure. When researchers conducted subgroup analyses, there was a borderline significant risk of lung cancer among nonsmokers exposed to passive smoking for more than 30 years versus women with no home exposure (HR = 1.61).
Women who are exposed to smoking in the home for greater than 30 years have an increased risk.
The analysis also found that women who smoke are 13 times more likely to develop lung cancer than those who have never smoked, but quitting significantly reduces this risk. The study, published in Annals of Oncology, used data from the Women's Health Initiative Observational Study cohort to investigate the relationship between active and passive smoking and lung cancer incidence in women.
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian Cancer
- Hormone Refractory Prostate Cancer Responds to Abiraterone Acetate in Some Cases
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- CQGS Releases Standards for Surgical Care of Older Adults
- Radiation Protocol Deviations Linked to Worse Outcomes in Pediatric Brain Malignancy
- Use of Counseling, Surgery Rates Show Limited Physician Knowledge of Breast Cancer Genetic Testing
- Family History Does Not Exclude Active Surveillance as Treatment Option for Prostate Cancer
- Beans, Whole Grains in Diet Beneficial for Colorectal Cancer Survivors
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|